Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 10/20 | 0.47 |
| ▸ | PPARA | Q07869 | 7/20 | 0.47 |
| ▸ | PPARG | P37231 | 5/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.41 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534770 | 0.90 | PPARD (0.50) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL3743776 | 0.89 | PPARD (0.42) | PPARDPPARAPPARGFFAR1MAPT | |
| SCHEMBL3756346 | 0.85 | PPARD (0.40) | PPARDPPARAPPARGFFAR1MAPT | |
| SCHEMBL3536414 | 0.83 | PPARD (0.62) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL3526094 | 0.80 | LMNA (0.36) | PPARDPPARAPPARGFFAR1MAPT | |
| SCHEMBL3545390 | 0.79 | PPARD (0.58) | PPARDPPARAPPARGFFAR1MAPT | |
| SCHEMBL3747886 | 0.77 | PPARD (0.40) | PPARDPPARAPPARGFFAR1MAPT | |
| SCHEMBL3536042 | 0.77 | PPARD (0.50) | PPARDPPARAPPARGFFAR1MAPT | |
| SCHEMBL3744972 | 0.76 | PPARD (0.39) | PPARDPPARAPPARGPLA2G2APLA2G10 | |
| SCHEMBL3752165 | 0.76 | PPARD (0.37) | PPARDPPARAPPARGFFAR1PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931660-B1 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-08-01 | — | — | EP | claimed |
| EP-1931660-B1 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-08-01 | — | — | EP | disclosed |
| US-7834030-B2 | Phenyl-[1,2,4]-oxadiazol-5-one derivatives, pharmaceutical compositions and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-16 | — | — | US | disclosed |
| US-20080262036-A1 | Phenyl-[1,2,4]-oxadiazol-5-one Derivatives, Pharmaceutical Compositions and Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| EP-1931660-A2 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007039178-A2 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262036-A1 | Phenyl-[1,2,4]-oxadiazol-5-one Derivatives, Pharmaceutical Compositions and Therapeutic Use Thereof | GPR119, CPT1A, PC | PPARD 63/4885PPARA 87/4885PPARG 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.